A new generation of cardiac sealant devices dissolves naturally in the body, closing congenital heart defects without leaving a permanent implant — reducing the risk of long-term complications.
• Bioabsorbable cardiac sealant — China-developed, fully degradable device for closing atrial septal defects and patent ductus arteriosus
• Complete degradation over 12–24 months — replaced by native tissue
• Reduced long-term complications — eliminates risks of metal allergy, erosion, and long-term thrombogenicity
I. Introduction: The Problem with Permanent Implants
Congenital heart defects — particularly atrial septal defects (ASD), ventricular septal defects (VSD), and patent ductus arteriosus (PDA) — have traditionally been treated with permanent metal or nitinol (nickel-titanium) occluder devices. While these devices are effective, they remain in the body for life, carrying risks of:
- Metal allergy — particularly to nickel, a common component of nitinol
- Device erosion — the device can erode through the heart wall in rare cases
- Thrombogenicity — permanent implants increase the risk of clot formation
- Arrhythmia — device-related conduction disturbances
- Interference with future procedures — the implant may obstruct later interventions
Bioabsorbable cardiac sealants address these limitations by providing a temporary scaffold that closes the defect and is gradually replaced by the body's own tissue.
I. Technology Overview
Material Science
China-developed bioabsorbable cardiac sealants are made from biodegradable polymers such as:
- Poly-L-lactic acid (PLLA) — a bioresorbable polymer with proven clinical history
- Polyglycolic acid (PGA) — enhances degradation profile
- Poly-D, L-lactic-co-glycolic acid (PLGA) — controlled degradation rate
Design Principles
The devices are designed with:
- Radial force — sufficient to occlude the defect and resist dislodgement
- Controlled degradation — maintaining structural integrity for 6–12 months while native tissue forms
- Complete resorption — fully degraded and excreted within 12–24 months
- Radiolucency — allows for future imaging without artifact
II. Clinical Evidence
Clinical studies of bioabsorbable cardiac sealants in China have demonstrated:
- Immediate closure rates — exceeding 90% immediately post-implantation
- Long-term closure — over 85% of patients maintain closure at 12-month follow-up
- Favorable safety profile — low rates of device-related complications
- Tissue ingrowth — histological studies confirm replacement of the device with native tissue
III. Regulatory Status
China's bioabsorbable cardiac sealants have received NMPA approval for specific indications, including:
- Atrial septal defect (ASD) — secundum type, defect diameter up to 30 mm
- Patent ductus arteriosus (PDA) — in pediatric and adult patients
IV. Advantages Over Permanent Devices
| Feature | Permanent Device | Bioabsorbable Sealant |
|---|---|---|
| Long-term retention | Permanent | Degrades completely |
| Metal allergy risk | Present (nitinol) | None |
| Erosion risk | Rare but serious | Significantly reduced |
| Imaging artifact | Significant | None |
| Future procedures | May interfere | No interference |
| Long-term tissue outcome | Foreign body | Native tissue replacement |
V. What This Means for International Patients
For international patients requiring interventional closure of congenital heart defects:
- Access to bioabsorbable technology — available in China before some Western countries
- Reduced long-term risks — avoiding the complications of permanent implants
- Cost advantage — interventional procedures in China are significantly more affordable
Conclusion
Bioabsorbable cardiac sealants represent a paradigm shift in the interventional treatment of congenital heart defects — moving from permanent implants to temporary, biodegradable devices that leave only native tissue behind. China is at the forefront of this innovation, offering patients a safer, more natural long-term outcome.